Trending Content - Investment Banking Forum
| +101 | [2026 - October] Unbiased Prestige Rankings | 61 | 12h |
| +94 | Who is the final boss in Houston Energy? (GS, JEFF or EVR) | 36 | 7h |
| +84 | You should probably leave IB | 28 | 14h |
| +46 | Tomorrow Will Be Better | 5 | 5d |
| +46 | Why Do We Turn Comments? | 11 | 1d |
| +41 | Moelis PCA vs Lower tier BB Coverage | 32 | 3h |
| +34 | Banking (Un)fortunately Still Needs You: My Case for Bankers in the AI Era | 9 | 8h |
| +28 | UBS IB #24 in US M&A in 2026 | 10 | 1d |
| +27 | Lateraling as Analyst | 25 | 1d |
| +24 | How much should you ask questions / seek feedback as an intern? | 9 | 1d |
Career Resources
Based on the most helpful WSO content, here’s what you need to know about exit opportunities from FIG, Healthcare, and NatRes/P&U/Infra groups at top BBs in Europe:
Financial Institutions Group (FIG):
Healthcare:
Natural Resources/Power & Utilities/Infrastructure (NatRes/P&U/Infra):
Generalist PE Transition:
In summary, while there is some risk of specialization in these groups, the prestige of your BB experience and the skills you develop can still open doors to generalist PE roles if you position yourself strategically.
Sources: Breakdown of Post-IB Exit Opportunities, Working in FIG (Financial Institutions Group) - An Overview., Breakdown of Post-IB Exit Opportunities, Why Should I Work in FIG Investment Banking?
FT or Intern?
Healthcare obviously not pigeonholed. What you are really asking is for FIG and NatRes.
Will speak on JP only, as that is what I know. No - not necessarily, you won't be pigeonholed.
EMEA FIG and EMEA NatRes has had exits into Tech PE / Biz services as well as Infra etc.
Really down to the individual I think because you get looks from HH either way
Thanks, it’s for a FT.
Why do you think Healthcare wouldn’t pigeonhole me? It seems like quite a specialised sector, with slightly different modelling, and over the long term I would have thought a life sciences background helps a lot. Or does Healthcare still offer solid exits into generalist corporate PE?
Not all of the deal flow is pure biotech though – a lot of it is EBITDA-driven (medtech, pharma services, providers), so still pretty relevant for generalist PE.
Thanks, that's very helpful
Mollitia culpa eligendi et. Harum molestias ipsam repellendus ipsum saepe quas quam. Molestias est illo commodi fugiat ab nostrum beatae. Illo et quam et fugiat facere ut esse. Eum amet dolor ut quia. Eligendi qui dolor voluptatibus laudantium hic totam.
Et et veniam ad earum est qui. Nihil excepturi id ipsum quis ut. Quia libero numquam quos voluptatem ullam. Facilis aut vel aut saepe ut natus eaque sed. Ex provident perspiciatis eaque sunt est.
Dolorem animi saepe earum autem. Molestias dolore excepturi voluptates quia.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...